Meghan, Duchess of Sussex opens up about ‘scary' condition after childbirth
Meghan, Duchess of Sussex has spoken about suffering from postpartum preeclampsia, calling the potentially fatal condition 'so rare and so scary.'
Speaking on the debut episode of her new podcast 'Confessions of a Female Founder,' released Tuesday, Meghan described her experience of the condition, which is marked by elevated blood pressure and high levels of protein in the urine or other signs of organ damage.
Meghan was speaking to her friend Whitney Wolfe Herd, founder of the Bumble dating app, who also experienced postpartum preeclampsia.
'We both had very similar experiences — though we didn't know each other at the time — with postpartum and we both had preeclampsia. Postpartum preeclampsia,' said Meghan.
'It's so rare and so scary,' she added.
Artwork produced for the launch of Meghan's new podcast.
Meghan, Duchess of Sussex
'And you're still trying to juggle all of these things, and the world doesn't know what's happening quietly,' said Meghan.
'And in the quiet, you're still trying to show up for people… mostly for your children, but those things are huge medical scares.'
Wolfe Herd agreed, saying: 'I mean life or death, truly. It's like, really scary.'
Most cases of postpartum preeclampsia develop within 48 hours of childbirth, but it can develop four to six weeks postpartum, according to the Mayo Clinic. Postpartum preeclampsia can cause seizures and other serious complications if left untreated.
Meghan shares two children with her husband, Prince Harry. Archie was born in May 2019 and Lilibet was born two years later, after the couple stepped down as working royals.
Meghan's new podcast is produced in partnership with Lemonada Media, which is home to Julia Louis-Dreyfus' podcast, 'Wiser Than Me with Julia Louis-Dreyfus,' 'Choice Words with Samantha Bee' and more.
After moving to the United States in 2020, Harry and Meghan secured numerous media deals, including with Spotify and Netflix, the streaming home of their docuseries, 'Harry & Meghan,' which chronicled their courtship, their relationship with the media and their decision to leave royal life.
And in March, her new Netflix show 'With Love, Meghan' was released on the streaming platform.
Consisting of eight glossy episodes, each centered around Meghan hosting a different friend, it offers tips and tricks for being the ultimate hostess, cook and homemaker. Netflix confirmed to CNN last month that the show has been renewed for a second season and is set to premiere in the fall.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
6 days ago
- Mid East Info
Mayo Clinic researchers validate blood test to diagnose Alzheimer's disease in outpatient memory clinics - Middle East Business News and Information
Dubai, United Arab Emirates;August 2025 — Alzheimer's disease, marked by memory loss, trouble concentrating and thinking, and changes in personality and behavior, devastates patients, their families and loved ones. With new treatments available for people with early signs of Alzheimer's disease, there is a growing need for accessible and cost-effective tests to diagnose the disease sooner. In a new study, Mayo Clinic researchers confirmed the accuracy of an FDA-approved blood test that can be used at outpatient memory clinics to diagnose the disease in patients with a range of cognitive impairment. The findings are published in Alzheimer's and Dementia: The Journal of the Alzheimer's Association. Standard ways of measuring the buildup of toxic proteins in the brain that indicate Alzheimer's disease include positron emission tomography, or PET scans, and spinal taps. But these tests can be expensive and invasive. More accessible, non-invasive and cost-effective biomarkers — measurable indicators of a disease — are needed to improve diagnoses broadly in clinical settings. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' says corresponding author Gregg Day, M.D., a Mayo Clinic neurologist, dementia specialist and clinical researcher. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' The research team says their findings show promise in: Better identifying research participants with Alzheimer's disease brain changes. Screening and selecting patients with Alzheimer's disease for clinical trials. Assessing how patients respond to therapy in clinical trials. More than 500 patients receiving treatment for a range of memory issues at the outpatient Memory Disorder Clinic at Mayo Clinic in Florida participated in the study. They included patients with early- and late-onset cognitive impairment, typical and atypical Alzheimer's disease, Lewy body dementia and vascular cognitive impairment. Patients ranged from 32 to 89 years old, with the average age of symptom onset being 66. Alzheimer's disease was determined to be the underlying cause of the symptoms in 56% of the patients. The team also conducted serum tests to measure kidney disease, which can influence plasma biomarker concentrations. Mayo Clinic Laboratories tested for two proteins in blood plasma that are associated with amyloid plaque buildup, the hallmark of Alzheimer's disease: Aβ42/40 and p-tau217. The researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Higher plasma p-tau217 concentrations were also associated with impaired kidney function, which researchers say should be taken into account when performing the blood test. Plasma p-tau217 concentrations were positive in 267 out of 509 patients, including 233 of 246 patients (95%) with cognitive impairment attributed to Alzheimer's disease. The study was featured at the American Academy of Neurology Annual Meeting in April. In a previous study, researchers from the Mayo Clinic Laboratories team showed the utility of these blood tests compared to amyloid PET scans in research participants. Dr. Day says the next steps in this research are to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's disease who show no cognitive symptoms. The team also wants to evaluate disease-specific factors that may alter biomarker accuracy in clinical trials. Other Mayo Clinic authors include Yoav Piura, M.D., Christian Lachner, M.D., Joshua Bornhorst, Ph.D., Alicia Algeciras Schimnich, Ph.D., and Neill Graff-Radford, M.D. For a full list of authors, funding and disclosures, see the paper.
Mid East Info
07-08-2025
- Mid East Info
Study finds long-term health benefits from bariatric surgery and liver transplant - Middle East Business News and Information
How obesity and liver disease are connected The percentage of liver transplant candidates in the U.S. with obesity continues to climb, with more than 41% of candidates having a body mass index above 30 in 2022. Obesity puts people at risk of developing metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease. It's a condition where excess fat accumulates in the liver, which can lead to inflammation, scarring and advanced liver disease. Patients with a body mass index of 40 are more likely to be denied a transplant due to their weight. 'Since MASLD is a leading cause of liver failure, it only makes sense to protect the precious, lifegiving new liver from the same damage that led to the patient needing a transplant in the first place. Safely combining the two procedures protects the transplanted liver and can provide profound health benefits to these patients,' says Todd Kellogg, M.D., Mayo Clinic bariatric surgeon and the study's co-author. What about using new prescription medications for weight loss? New weight loss medications, such as GLP-1s, are being used to help some pre-transplant and post-transplant patients manage their weight. Still, Mayo Clinic experts say bariatric surgery remains an important option for patients with severe obesity due to its safety, proven effectiveness and lasting results. Another recent Mayo study related to kidney transplant patients supports this. 'The patients that we're talking about really have a significant amount of extra weight. The issue with the GLP-1 medications is they are effective in terms of weight loss as well as other benefits which are being identified, but they may not get these patients with severe obesity to their lasting goal of a healthier weight,' Dr. Heimbach says.
Mid East Info
31-07-2025
- Mid East Info
Mayo Clinic discovery could mean better access to more donor hearts and improved transplant outcomes - Middle East Business News and Information
Dubai, United Arab Emirates; July 2025 — A new discovery by Mayo Clinic researchers could mean more donor hearts are available for heart transplant, giving more people a second chance at life. In findings published in Nature Cardiovascular Research, a team led by Mayo Clinic cardiac surgeon Paul Tang, M.D., Ph.D., identified a biological process that contributes to donor heart injury during cold storage. The researchers found that a drug already used to treat heart conditions can prevent this damage. Heart transplantation is the most effective treatment for end-stage heart failure, yet fewer than half of donor hearts are ultimately used. One major reason is the relatively short window for transplanting a donated heart into a patient, due to concerns over low donor heart function that comes from leaving a heart in cold storage too long. Why donor hearts deteriorate in cold storage: Although cold storage slows metabolism and helps preserve tissue, prolonged exposure to cold storage conditions can lead to molecular changes that compromise how well the heart performs after transplant. One complication is called primary graft dysfunction, in which the transplanted heart cannot pump blood effectively after surgery. This may affect up to 20% of recipients to varying degrees. To investigate why this damage occurs, the researchers focused on a protein inside heart cells called the mineralocorticoid receptor, which plays a role in how cells respond to stress. During cold storage, they found that this protein undergoes a process in which the protein clumps together in a way that harms the heart cells, called liquid-liquid phase separation. This process promotes cardiac damage from increased inflammation and cell death, making the heart less likely to function well after transplant. Preventing damage with a common drug: To test whether the process could be prevented, the researchers treated donor hearts with a drug called canrenone, which blocks mineralocorticoid receptor activity. In human donor hearts stored beyond the typical timeframe, treatment with the drug nearly tripled their pumping strength compared to hearts stored without it. The hearts also showed better blood flow and fewer signs of cell injury. The findings suggest canrenone may help extend the safe storage period for donor hearts by improving the heart's pumping strength to increase chances of a successful transplant. 'As a cardiovascular surgeon, I've personally experienced in the operating room how every additional hour of preservation can impact the likelihood of whether a donor heart can return to normal function after transplantation,' Dr. Tang says. 'This discovery may give us a new tool to preserve heart function for longer during storage, improve transplant outcomes and enhance patient access to lifesaving transplants.' The study's findings also have the potential to improve the preservation of other transplantable organs. Similar protein clustering was observed in donor kidneys, lungs and livers during cold storage. This suggests that the same strategy may help expand transplant options across multiple organ systems.
